LivaNova PLC Market Research Report
Company Overview
- Name: LivaNova PLC
- Mission: Provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the head and heart.
- Founding Information: Information not available.
- Key People:
- Vladimir Makatsaria - Chief Executive Officer
- Stephanie Bolton - President, Global Epilepsy
- Michael Hutchinson - Senior Vice President, Chief Legal Officer and Company Secretary
- Philip Kowalczyk - Chief Strategy and Corporate Development Officer
- Natalia Kozmina - Chief Human Resources Officer
- Sujay Mashru - Vice President, APAC and Growth Markets
- Franco Poletti - President, Cardiopulmonary
- Alex Shvartsburg - Chief Financial Officer
- Ahmet Tezel - Chief Innovation Officer
- William Kozy - Chair of the Board
- Headquarters: 20 Eastbourne Terrace, London, W2 6LG, United Kingdom
- Number of Employees: Approximately 2,900
- Revenue: No information is available.
- Company Known For: LivaNova is a global medtech company focused on delivering innovative health solutions in cardiopulmonary, drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea.
Products
1. Essenz™ Perfusion System
- Description: Part of a comprehensive range of solutions for cardiopulmonary bypass during open-heart surgery. Known for being the world's No. 1 heart-lung machine.
- Key Features: Enhanced perfusion management, globally recognized.
2. VNS Therapy™ for Epilepsy
- Description: A therapy system for drug-resistant epilepsy intended to manage and control seizures.
- Key Features: Treatment for over 125,000 patients globally, reduces seizure frequency and severity.
3. VNS Therapy™ for Depression (SYMMETRY™)
- Description: This system aims to treat depression that is difficult to manage with conventional methods.
- Key Features: Shown to improve symptoms, part of the RECOVER clinical study.
4. Sleep Apnea Implant Therapy (THN Sleep Therapy™)
- Description: A treatment option for obstructive sleep apnea involving an implantable device.
- Key Features: Alternatives to CPAP with hypoglossal nerve stimulation, investigational use in the U.S.
Recent Developments
- Recent Developments: No specific information on recent developments.
- New Products Launched: No information is available.
- New Features Added: No information is available.
- New Partnerships: No information is available.
Additional Information
- Sustainability Strategy:
- LivaNova is committed to sustainability, setting targets for carbon reduction and expanding efforts in responsible packaging.
- Targets include a reduction of Scope 1 and 2 emissions by 54.6% and Scope 3 emissions by 27.5% by 2033.
- Ethics and Compliance:
- The company upholds a strong Code of Conduct, advocating for transparency and ethical practices among employees and third parties.
- LivaNova maintains a robust ethics line and policies to safeguard whistleblowers.
This report provides a snapshot of LivaNova PLC from the perspectives of their mission, leadership, product offerings, and strategic sustainability commitments. Further detailed financial data or strategic business shifts would require additional data not available in this report.
